Skip to main content
    V

    VistaGen Therapeutics Inc (VTGN)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $0.19
    +0.00 (+2.01%)

    Market Cap: $8.01M

    Last updated: Nov 17, 2026 at 4:15 PM ET

    VistaGen Therapeutics Inc (VTGN) Statistics

    Updated Nov 17, 2026. Figures from company filings and market prices; estimates from consensus analysts.

    VistaGen Therapeutics (VTGN) has a market cap of $8.01M. It kept -2475.56% of revenue as net income over the last 12 months. Revenue grew 230.24% over the last 12 months from the 12 months before.

    Total Valuation

    Market Cap$8.01M
    Latest price (Nov 17, 2026)$0.19

    Key Dates

    The next earnings report is expected on Feb 10, 2027, covering the quarter ending Dec 31, 2026.

    Next Earnings DateFeb 10, 2027 (expected)
    Last Earnings DateNov 13, 2026
    Fiscal Year EndMarch

    Share Statistics

    The share count rose 3.40% in the quarter ended Sep 30, 2026 and grew 20.45% a year over 2 years.

    Shares Outstanding44.44M
    Shares Change (YoY)+24.31%
    Shares Change (QoQ)+3.40%
    Share Count Growth (2Y CAGR)+20.45%

    Valuation Ratios

    Sales and book value multiples are 3.5x and 0.6x. Its year-end P/S ranged from 7.6x to 375.7x from 2017 to 2025.

    P/S Ratio3.5x
    Forward P/S4.7x
    P/B Ratio0.6x

    Valuation history and multiples

    Price Statistics

    The stock is down 95.05% over 52 weeks and trades 13.64% below its 50-day average.

    Beta (1Y)1.88
    52-Week Change-95.05%
    1-Month Change-7.43%
    3-Month Change-22.98%
    6-Month Change-70.16%
    5-Year Change-99.76%
    10-Year Change-99.86%
    Total Return (1Y)-95.05%
    Total Return (3Y CAGR)-61.82%
    Total Return (5Y CAGR)-69.06%
    Max Drawdown (1Y)-96.66%
    Max Drawdown (3Y)-97.16%
    Sharpe Ratio (1Y)-1.46
    Correlation with SPY (1Y)0.12
    50-Day Average$0.22
    200-Day Average$0.42
    52-Week Range$0.16 to $5.14
    RSI (14 Days)47.5
    Average Volume (20 Days)757.73K

    The 5 and 10 year changes compare month-end closes, adjusted for splits, through Oct 2026.

    Price chart

    Financial Position

    Current assets cover 2.64x current liabilities, and total debt is 0.00x shareholder equity.

    Current Ratio2.64x
    Quick Ratio2.64x
    Debt / Equity0.00x

    Returns and Efficiency

    Return on equity is -393.16% and return on assets is -251.67% over the last 12 months.

    Return on Equity (ROE)-393.16%
    Return on Assets (ROA)-251.67%
    Asset Turnover0.05x

    Scores

    VTGN has an Altman Z-Score of -37.08, in the distress zone below 1.81, and a Piotroski F-Score of 2 of 9, in the weak band of 0 to 2.

    Altman Z-Score-37.08
    Altman Z ZoneDistress
    Piotroski F-Score2 of 9
    Piotroski StrengthWeak

    Income Statement

    Revenue was $2.38M over the last 12 months.

    Revenue$2.38M
    Revenue Growth (YoY)+230.24%
    Gross Profit$2.38M
    Operating Income-$60.55M
    Pretax Income-$58.94M
    Net Income-$58.94M
    Reported EPS (TTM)-$1.36

    Trailing 12 months through Sep 30, 2026.

    Full financial statements

    Balance Sheet

    Shareholder equity funds 64.01% of the $23.42M in total assets.

    Cash and Equivalents$10.89M
    Total Debt$0
    Net Cash$10.89M
    Net Cash Per Share$0.25
    Working Capital$13.87M
    Shareholder Equity$14.99M
    Book Value Per Share$0.34
    Total Assets$23.42M
    Total Liabilities$8.43M

    Balance sheet as of Sep 30, 2026.

    Full balance sheet

    Cash Flow

    Operating Cash Flow-$60.70M
    FCF Per Share-$1.37
    Depreciation and Amortization$769.00K

    Trailing 12 months through Sep 30, 2026.

    Full cash flow statement

    Margins

    The operating margin is -2543.22%.

    Gross Margin100.00%
    Operating Margin-2543.22%
    Pretax Margin-2475.26%
    Net Margin-2475.56%

    Growth

    Revenue Growth (5Y CAGR)+3.10%
    Book Value Per Share Growth (2Y CAGR)-53.03%
    Tangible Book Per Share Growth (2Y CAGR)-53.03%

    Revenue and profit by year

    Dividends and Yields

    VTGN does not pay a dividend.

    Buyback Yield-44.80%
    Shareholder Yield-44.80%

    Stock Splits

    The last split was a 1-for-30 reverse split on Jun 7, 2023.

    Last Split DateJun 7, 2023
    Split TypeReverse split
    Split Ratio1:30

    Analyst Forecast

    Consensus estimates put revenue growth at 33.96% a year over the next fiscal year.

    Revenue Growth Forecast (1Y CAGR)+33.96%

    Analyst estimates by year

    Price Target

    Analyst price targets are part of paid GNG plans. See plans

    GNG Valuation

    GNG viewUndervalued

    GNG fair value is part of GNG Pro. See plans

    Frequently Asked Questions About VTGN

    What is VTGN's market cap?

    VistaGen Therapeutics has a market cap of $8.01M.

    How many shares of VTGN are outstanding?

    VistaGen Therapeutics has 44.44M shares outstanding. The count is up 24.31% from a year earlier.

    Does VTGN pay a dividend?

    No. VistaGen Therapeutics does not pay a dividend.

    How much debt does VTGN have?

    VistaGen Therapeutics has $0 of total debt and $10.89M of cash and equivalents, a net cash position of $10.89M.